The TNM staging system for colorectal cancer (CRC) stratifies patients into stages, which influences their treatment pathway; this is especially true for rectal cancer where treatment ranges from local polyp resection to neoadjuvant chemoradiotherapy, surgery and adjuvant chemotherapy. However, there are many flaws with this staging system, including the prognostic heterogeneity of patients with cancers at the same stage ([@bib40]; [@bib6]), as well as under- and overtreatment of patient subsets ([@bib40]; [@bib43]; [@bib64]; [@bib30]; [@bib31]), and no superior method of staging and prognostication is currently validated ([@bib11]). The future of CRC care will rely on accurate staging and prognostic algorithms, potentially with the addition of demographic, biochemical, morphological, molecular and treatment-related parameters to improve accuracy. One such parameter for inclusion is tumour budding, a histological phenomenon in epithelial cancers when tumour cells or cell clusters migrate into the surrounding stroma by detaching from the invasive tumour front ([@bib42]; [@bib15]; [@bib71]). It represents de-differentiation of epithelial cells into more invasive phenotypes in a process known as epithelial--mesenchymal transition (EMT; [@bib21]).

Tumour budding in CRC has been shown significantly associated with lymphatic invasion ([@bib42]; [@bib49], [@bib50]; [@bib51]; [@bib34]; [@bib10]; [@bib48]; [@bib77]), and accordingly has a well-established association with lymph node metastases, and is a negative prognostic indicator in terms of recurrence and overall survival ([@bib70], [@bib72]; [@bib36]; [@bib77]; [@bib24]; [@bib52]). An association with distant metastases has also been documented ([@bib46]; [@bib66]).

Despite this, tumour budding has not been incorporated into the TNM staging of CRC, partly due to the disagreements in its definition and identification, with 'concerns over reproducibility of assessment, and the wide ranges of percentage of colorectal tumours reported to show budding in different studies\' ([@bib35]).

One other obstacle when trying to introduce budding in clinical practice is the fact that some methods for reporting are conceived for early stages (I--II) and some are for advanced disease (III); therefore, it is difficult to choose a method suitable for all stages.

The aim of the current study was to perform a systematic review and meta-analysis of the implications of tumour budding in operable CRC resection specimens on lymph node metastases, recurrence and cancer-related death.

Materials and methods
=====================

Search protocol
---------------

Original studies were searched for those that documented patients with surgically resected primary colorectal adenocarcinoma, where the specimens were assessed for the presence of tumour budding. The outcome measures chosen were lymph node metastases at resection, rates of recurrence and 5-year cancer-specific survival rates. Embase, Medline, PubMed, PubMed Central and Cochrane databases were searched using the following Boolean search term: budding AND (cancer OR carcinoma OR adenocarcinoma OR tumor OR tumour) for articles published up to March 2016. All search results were combined in a reference manager database (Endnote) and duplicates removed. Reference lists of included studies were also searched. The inclusion and exclusion criteria are shown in [Figure 1](#fig1){ref-type="fig"}.

Data extraction
---------------

Two independent reviewers applied the inclusion criteria to retrieved study abstracts and selected full papers for data analysis. These same two reviewers extracted data from full text papers and applied exclusion criteria in order to identify the final included studies; discrepancies were verified by consensus. If multiple publications reported results in the same population, the most recent report or most comprehensive data were chosen. For each study, data on baseline characteristics (author institution, country, study period, total number of patients, sex, site of cancer, stage, histology, budding definition and methodology) were extracted. The number of patients exhibiting budding, those with co-existing lymph node metastases, merged rates of local or distant recurrence and 5-year cancer-related death rates were obtained where available. We described outcomes as odds ratios with 95% confidence intervals. Where these were not presented in a paper, we followed methods described by Parmar to extract them from Kaplan--Meier curves, or percentage survival. We contacted authors if data were not presented in a useable form.

Budding definition
------------------

There remains to be a consensus on the most accurate method of assessing tumour budding; currently there are variations in the cut-off for presence or absence of tumour budding -- some groups use ⩾1 budding focus to define the presence of tumour budding, whereas other groups use \>4 or \>9 foci. For this reason, the defined term was catalogued from each included paper and displayed in the results. In papers where two methods of identifying tumour budding were evaluated, the results of the standard method were used for analysis. For the analysis, budding was determined to be either present or absent. Where budding was graded into groups (e.g., mild/moderate/severe), the results for the mild/moderate groups were combined and compared with the severe or highest grade group.

Quality analysis
----------------

This meta-analysis was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. We measured the quality of the studies on the basis of the Newcastle--Ottawa Scale that assesses the methodological quality of non-randomised cohort studies for meta-analysis. The studies were judged by two independent assessors using a nine-point scale comprising analysis on the selection of the study group, the comparability of cohorts and the ascertainment of outcome. Scores above 6 points were taken to denote studies of high methodological quality.

Statistical analysis
--------------------

All analyses were conducted with the RevMan statistical package (Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Heterogeneity between studies for each of the outcome measures was tested with Cochran\'s Q test. The *I*^2^ statistic was calculated for an objective measure of heterogeneity. A fixed-effects meta-analysis was performed in all cases, and where there was appreciable heterogeneity (*I*^2^\>50% or chi-squared *P*-values \<0.10) a random-effects model was also used for meta-analysis. Corresponding funnel plots of Ln standard error as a function of effect size were used to examine the effect of publication bias visually, and were statistically tested using Eggers test. *P*-values \>0.05 were indicative of no publication bias. For meta-analysis, Mantel--Haenszel odds ratios for lymph node metastasis, recurrence and 5-year cancer-related death were extracted and described with 95% confidence intervals. Sensitivity analysis was performed to identify if any methodological features were indicative of heterogeneity among studies. Studies were excluded if they had poor methodological quality (Newcastle--Ottawa scores \<7), where the definitions of tumour budding were unclear or not predetermined in the Methods section, or where the rate of tumour budding in the study was outside of the mean rate of tumour budding among all studies±1 s.d. from the mean. Subgroup analysis was also carried out to compare whether tumour location (colon or rectum), T stage (some studies only included T1 and T2 tumours) and lymph node status affected results.

Results
=======

Search results
--------------

The literature search revealed 2728 publications ([Figure 2](#fig2){ref-type="fig"}). Of the 143 included for full text review, 34 were ultimately included in the meta-analysis ([@bib15]; [@bib70]; [@bib49], [@bib50]; [@bib72]; [@bib54]; [@bib76]; [@bib83]; [@bib22]; [@bib45]; [@bib82]; [@bib36]; [@bib48]; [@bib77]; [@bib16]; [@bib20]; [@bib28]; [@bib67]; [@bib1]; [@bib57]; [@bib4]; [@bib44]; [@bib65]; [@bib84]; [@bib75]; [@bib18]; [@bib29]; [@bib47]; [@bib60]; [@bib12]; [@bib38]; [@bib41]; [@bib69]; [@bib3]). There were a total of 7821 patients included for analysis, with study groups ranging from 58 to 1114 patients. All studies were conducted in Europe or Asia. The main characteristics of eligible studies are characterised in [Table 1](#tbl1){ref-type="table"}. Most studies were retrospective and included patients with colon and rectal cancers from a mixture of stages. One study included patients with metastases at diagnosis ([@bib22]); these patients were excluded for analysis of disease recurrence and so the non-metastatic data are included here. There were 25 studies that correlated tumour budding status with lymph node metastases in the specimen, 12 that examined recurrence rates, and 9 that documented 5-year cancer-related death rates. The mean rate of tumour budding was 36.8±16.5%.

Quality of studies
------------------

The Newcastle--Ottawa scaling method assessed the methodological quality of the studies and scores are outlined in [Table 1](#tbl1){ref-type="table"}, with an overview of the scoring system method in [Supplementary Material 1](#sup1){ref-type="supplementary-material"} and raw scores in [Supplementary Material 2](#sup1){ref-type="supplementary-material"}. The majority (81.6%) of studies had quality scores ⩾7, indicating good methodological quality of included studies, and four studies (15.6% [@bib16]; [@bib57]; [@bib65]; [@bib29]) had acceptable scores of 6.

Definitions of tumour budding
-----------------------------

There were considerable differences and an overt lack of standardisation of tumour budding between studies ([Table 2](#tbl2){ref-type="table"}). Twenty-eight studies used standard haematoxylin and eosin (H&E) staining, four studies used immunohistochemistry (IHC) and cytokeratin staining ([@bib54]; [@bib36]; [@bib48]; [@bib84]), and two did not specify the technique ([@bib12]; [@bib38]), although one could assume standard H&E was used. A 'budding focus\' or its equivalent was defined as an isolated cancer cell or cluster of less than five cells in 24 studies. The remaining studies were either unclear about the definition of a budding focus ([@bib83]; [@bib22]; [@bib45]) or defined it as an isolated cancer cell or cluster of less than six cells ([@bib49]; [@bib36]; [@bib57]; [@bib44]; [@bib84]), or a cluster of greater than four cancer cells ([@bib50]; [@bib76]). Tumour budding was then defined according to the number of budding foci in the majority of studies; there was some heterogeneity with the classifications between studies. Ten studies identified tumour budding positivity if there were \>4 budding foci present in the specimen. Other studies used \>9 budding foci (eight studies), ⩾1 focus (five studies), \>5 foci (three studies), \>10, \>16 or \>24 foci (one study each). Three studies did not quantify the number of budding foci, but graded tumour budding as mild, moderate or severe, depending on subjective opinion ([@bib15]) or the proportion of the tumour margin involved by budding ([@bib22]; [@bib45]). For these studies, the severe group data were compared with mild and moderate ([@bib22]; [@bib45]). One study was unclear as to the methodology used to determine tumour budding ([@bib16]).

Meta-analysis results
---------------------

### Lymph node metastasis

There were 25 included studies that compared the rate of tumour budding to regional lymph node metastases in the resected specimens, involving 6724 patients. The pooled random-effects analysis suggested that specimens exhibiting tumour budding were significantly associated with lymph node positivity (OR 4.94, 95% CI 3.96--6.17, *P*\<0.00001; [Figure 3](#fig3){ref-type="fig"}). There was moderate heterogeneity between the studies (*I*^2^=53%) and thus a random-effects model is shown. When sensitivity analysis was performed, omission of those studies with Newcastle--Ottawa quality scores \<7, those with an unclear definition of tumour budding or those which had overall rates of tumour budding outside of 1 s.d. of the mean tumour budding rate did not alter the overall effect of tumour budding on lymph node metastasis or affect heterogeneity (OR 4.90, CI 3.90--6.16, *I*^2^=55%, OR 5.13, CI 4.02--6.53, *I*^2^=52% and OR 3.98, CI 2.96--5.35, *I*^2^=54%, respectively). Subgroup analysis of studies by tumour location improved homogeneity; those that included rectal cancer only had an *I*^2^ of 0%, with a fixed-effects model OR remaining significant at 5.36, CI 4.25--6.75. Only one study in this group included colon cancer only. The remaining studies did not differentiate between colon and rectal cancers and had an OR for lymph node metastasis similar to the overall study group (OR 4.83, CI 3.61--6.45, *I*^2^=59%). Fourteen studies only examined lymph node metastases in T1 and T2 tumours, this group was also heterogeneous (*I*^2^=52%) with an OR of 5.67, CI 3.92--8.21. Conversely, the 11 studies that did not differentiate between T stage were also heterogeneous with *I*^2^=58% and OR 4.52, CI 3.39--6.02.

### Local or distant recurrence

Twelve studies compared the rate of tumour budding with local or distant recurrence, involving 2773 patients. The pooled random-effects analysis suggested that specimens exhibiting tumour budding were significantly more likely to develop disease recurrence over the time period (OR 5.50, 95% CI 3.64--8.29, *P*\<0.00001; [Figure 4](#fig4){ref-type="fig"}). There was moderate heterogeneity between the studies (*I*^2^=61%). Sensitivity analysis with omission of studies of poor methodological quality or those with unclear definitions of tumour budding did not change the effect of tumour budding on disease recurrence or affect heterogeneity results (OR 5.48, CI 3.35--8.97, *I*^2^=68% and OR 5.01, CI 2.88--8.73, *I*^2^=65%). Exclusion of studies with outlying rates of overall tumour budding did not improve heterogeneity with an *I*^2^ of 56%, and an OR of 4.54, CI 2.75--7.49. Subgroup analysis by tumour location could not be performed, as only one included study focussed on rectal cancer in relation to recurrence. In the group that examined recurrence in T1/T2 tumours only, three studies had a heterogeneous *I*^2^ of 50%, OR 2.87, CI 1.12--7.35. The remaining nine studies did not stratify by T stage and displayed improved homogeneity (*I*^2^=42%) and a fixed effects OR of 7.41, CI 5.77--9.50. In the four studies that only examined recurrence in node negative resections, the fixed-effects model gave an OR of 6.57, CI 4.18--10.32, *I*^2^=0%. The remaining seven studies included both node negative and node positive disease, and were heterogeneous (*I*^2^=75%), OR 4.91, CI 2.63--9.17.

### Five-year cancer-related death rates

The rate of tumour budding with 5-year cancer-related death was documented in nine studies, involving 2234 patients. When analysed using a pooled random-effects model, the results demonstrate that CRCs with tumour budding were significantly more likely to lead to cancer-related death at 5 years (OR 4.51, 95% CI 2.55--7.99, *P*\<0.00001; [Figure 5](#fig5){ref-type="fig"}). There was significant heterogeneity between the studies (*I*^2^=78%) and thus a random-effects model is shown. Sensitivity analysis excluding studies with Newcastle--Ottawa quality scores \<7 and those with unclearly defined criteria for tumour budding did not change the overall effect of tumour budding on 5-year cancer-related death rates or on heterogeneity between studies (OR 4.39, CI 2.32--8.30, *I*^2^=80% and OR 3.58, CI 1.61--7.99, *I*^2^=85%). Including only those studies with rates of tumour budding within 1 s.d. of the overall mean rate improved *I*^2^ to 0%, with a fixed-effects model OR of 7.43, CI 5.84--9.45. Subgroup analysis by tumour location included two studies examining tumour budding with relation to 5-year cancer-related death in rectal cancer, OR 6.97, CI 5.29--9.19, *I*^2^=0%. Three studies included only colon cancers for analysis, OR 7.71, CI 4.46--13.33, *I*^2^=6%. The remaining four studies did not differentiate between colon and rectal cancers and were heterogeneous, *I*^2^=82%, OR 2.59, CI 0.85--7.92. Only one study examined 5-year cancer-related death in those with early (T1/T2) tumours, but when this was excluded, the remaining studies were homogenous (*I*^2^=0%) with the fixed-effects model giving a significant OR of 6.50, CI 5.19--8.14. Where node negative tumours only were included, the four studies were homogenous (*I*^2^=0%), with an OR of 5.43, CI 3.31--8.91, on the fixed-effects model. The remaining studies included node negative and positive disease and were heterogeneous (*I*^2^=89%), OR 3.86, CI 1.43--10.41.

Publication bias
----------------

Funnel plots were created for each outcome measure. The shapes of the funnel plots and the statistical tests revealed no evidence of bias in any of the three groups (*P*-values for lymph node metastasis, recurrence and 5-year cancer-related death were 0.103, 0.402 and 0.363, respectively; [Figure 6](#fig6){ref-type="fig"}).

Discussion
==========

The meta-analysis demonstrates that the histopathologic finding of tumour budding in resected CRC specimens is associated with concurrent lymph node metastases, disease recurrence and cancer-related death, despite variations in tumour budding definition between included studies. Tumour budding appears to indicate an aggressive phenotype, independent of staging according to the current TNM guidelines. Personalised patient care is an emerging concept in the future of cancer treatment ([@bib53]; [@bib79]; [@bib19]), and incorporation of tumour budding into the staging of CRC could assist in tailoring the management of currently contentious subgroups ([@bib26]). Tumour budding may indicate early colorectal tumours requiring more rigorous treatment approaches, or its absence may aid decision-making in later stage cancers.

At present there is no proven benefit in treating early stage CRC patients with chemotherapy ([@bib56]; [@bib68]); however, we know there are subsets of stage I and II CRC who have poor prognostic outcomes. Although the current results suggest that tumour budding identifies high-risk early stage CRCs, it remains to be determined whether its presence indicates the need for further treatment in this subset. Clinical trials stratifying patients according to tumour budding status may be warranted.

Studies have also looked at tumour budding in other epithelial cancers, demonstrating a negative prognostic impact in oesophageal ([@bib27]; [@bib7]), breast ([@bib62]), pancreatic ([@bib23]) and lung ([@bib39]) carcinomas, but as yet, tumour budding remains a non-core component of colorectal adenocarcinoma pathologic staging ([@bib26]) and is not formally part of staging of other cancers. Most studies advocate its identification using standard pathologic processing methods (H&E, light microscopy), with no extra staining or pathological processing required -- thus this is potentially a cost-effective addition to current staging protocols. Cytokeratin staining appears to assist tumour budding detection and may be worthwhile investigating further ([@bib66]; [@bib55]). Interestingly, although studies vary in their definition of how many cells constitute a tumour bud, and how many buds represent budding, and with considerable inter-observer variability in its reporting, most studies definitively demonstrate that the finding is a strong negative prognostic marker in CRC. A recent systematic review summarises methods of identifying tumour budding and their relationship to prognosticating CRC and surmises that despite differences in methodologies between studies, 'most methods, if practised with care and some training, will yield relevant prognostic information as high-degree tumour budding places a patient at a significant risk for an adverse outcome\' ([@bib73]). However, it is clear that the definition needs standardisation, and for this, more prospective trials need to be designed to assess its reproducibility and inter-observer variation.

As the search herein was performed, other studies have also supported a negative prognostic role of tumour budding in CRC ([@bib2]; [@bib13]). Petrelli *et al* ([@bib52]) recently undertook a systematic review of tumour budding and its relation to survival limited to stage II CRC. Their meta-analysis includes 10 studies and compares favourably with ours in that it also demonstrates a significantly increased OR for death at 5 years (OR 6.25, 95% CI 4.04--9.67, *P*\<0.00001).

The results herein strongly demonstrate that tumour budding is a negative prognostic indicator in almost 7000 patients with CRC -- these results remain robust even with sensitivity and subgroup analyses. Interestingly, when sensitivity analysis was performed only to include those studies with a percentage finding of tumour budding within 1 s.d. above and below the mean for all patients, the heterogeneity on the studies significantly decreased. This provides further evidence that standardisation of the definition and characterisation is imperative in the future of CRC staging.

Staging of CRC using the TNM system is notoriously inaccurate for prognosticating patient subsets, and thus many other prognostic markers have been studied. These include circulating and tumour markers such as cyclin D1 expression, CXCR4, VEGF, microRNA-21, survivin, CDKN2A hypermethylation, BRAF and K-ras mutation, as well as the findings of microsatellite instability, mucinous tumour phenotype and a high neutrophil--lymphocyte ratio ([@bib14]; [@bib9]; [@bib61]; [@bib74]; [@bib17]; [@bib80]; [@bib81]; [@bib37]; [@bib78]; [@bib32], [@bib33]; [@bib59]). Despite the fact that all are negative prognostic markers for overall survival in CRC, none have pooled hazard or odds ratios \>2 on systematic review. Even more well-established prognostic indicators such as perineural invasion and high lymph node ratio are associated with relative risks for poorer overall survival of \<2.5 ([@bib8]; [@bib25]). The results of the current study demonstrate that tumour budding has an effect on survival that is markedly worse than any other previously studied pathological phenotype, with an OR of 4.5 for cancer-related death at 5 years in those exhibiting tumour budding. These findings support its inclusion into CRC pathologic staging as a marker of a more aggressive disease phenotype.

Early evidence suggests that tumours exhibiting budding do not respond to neoadjuvant chemotherapy ([@bib5]; [@bib58]; [@bib63]). In this study, we excluded rectal cancers undergoing neoadjuvant chemoradiotherapy (nCRT). Although this subset of included rectal tumours are likely to be less advanced, we felt that nCRT inclusion may weaken the data, and a further meta-analysis of this subset is warranted when more results are available. It remains to be determined whether tumour budding should be seen as an indicator for a primary surgical approach in rectal cancer and foregoing nCRT as these patients are less likely to respond; more data are required to elucidate this point. However, those tumours exhibiting budding certainly are worth considering as a subset to target with adjuvant chemotherapy in CRC as a whole.

Tumour budding in CRC is strongly predictive of lymph node metastases, recurrence and cancer-related death at 5 years. Incorporation of this histological finding into the CRC staging algorithm is imminent, but will require standardisation of the pathological description of tumour budding.
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![**Study inclusion and exclusion criteria.**](bjc2016274f1){#fig1}

![**Flow diagram of the systematic review and meta-analysis process.**](bjc2016274f2){#fig2}

![**The association of tumour budding with lymph node metastasis in resected colorectal cancer.**](bjc2016274f3){#fig3}

![**The association of tumour budding with local or distal recurrence in resected colorectal cancer.**](bjc2016274f4){#fig4}

![**The association of tumour budding with 5-year cancer-related death in resected colorectal cancer.**](bjc2016274f5){#fig5}

![**Funnel plots for visual inspection of publication bias.** Each point represents a standardised comparison of a separate study, comparing the outcome effect (OR) with the standard error of its logarithm (SE(log\[OR\])). (**A**) Lymph node metastases, (**B**) recurrence, (**C**) 5-year cancer-related death.](bjc2016274f6){#fig6}

###### Overview of included studies

                                                                     **AJCC stage**              
  ------------------- ------ ------------- ------------ ---- ------ ---------------- --- --- --- ---
  Hase                 1993  Japan         1970--1985    CR   663          ✓          ✓   ✓       7
  Ueno                 2002  Japan         1981--1994    R    437                         ✓       7
  Okuyama              2003  Japan         1985--1997    C    196                     ✓   ✓       8
  Okuyama              2003  Japan         1985--1997    R     83                     ✓   ✓       7
  Ueno                 2004  Japan         1960--1980    R    1114         ✓          ✓   ✓       9
  Prall                2005  Germany       1994--1999    CR   182          ✓          ✓           8
  Wang                 2005  China         1969--2002    CR   159          ✓              ✓       8
  Yasuda               2007  Japan         NA            CR    86          ✓              ✓       7
  Kanazawa             2008  Japan         1996--2001    CR   133                     ✓   ✓   ✓   7
  Nakamura             2008  Japan         1986--1998    C    200                     ✓           7
  Yamauchi             2008  Japan         1991--2001    CR   164          ✓              ✓       8
  Lugli                2009  Switzerland   1987--1996    CR   273          ✓          ✓   ✓       7
  Ogawa                2009  Japan         1995--2003    CR    83          ✓              ✓       8
  Wang                 2009  Ireland       1990--2004    CR   128                     ✓           9
  Homma                2010  Japan         2000--2007    R     65          ✓              ✓       6
  Kajiwara             2010  Japan         1985--2005    CR   244          ✓              ✓       8
  Komori               2010  Japan         1990--2004    CR   111          ✓              ✓       8
  Tateishi             2010  Japan         1992--2005    CR   322          ✓              ✓       8
  Akishima-Fukasawa    2011  Japan         1989--2009    CR   111          ✓              ✓       7
  Reggiani Bonetti     2011  Italy         1989--2004    CR    95          ✓              ✓       6
  Betge                2012  Austria       1984--2005    CR   110                     ✓           8
  Nakadoi              2012  Japan         1981--2008    CR   499          ✓              ✓       8
  Sert Bektas          2012  Turkey        2003--2007    CR    73          ✓          ✓   ✓       6
  Wada                 2013  Japan         1995--2005    CR   120          ✓              ✓       8
  Zlobec               2012  Switzerland   1987--1996    CR   127          ✓          ✓   ✓       8
  Nishida              2014  Japan         2000--2011    CR   265          ✓              ✓       8
  Huh                  2014  Korea         2007--2009    CR   543          ✓              ✓       8
  Lai                  2014  China         1999--2007    C    135                     ✓           6
  Ryu                  2014  Korea         2003--2012    CR   179          ✓              ✓       8
  Gilardoni            2015  Italy         2006--2009    C    196          ✓          ✓           8
  Macias-Garcia        2015  Spain         2000--2011    CR    97          ✓                      8
  Tristante            2015  Spain         2011--2014    CR    58                     ✓   ✓       4
  Barresi              2016  Italy         NA            CR    82                     ✓           7
  Miyachi              2016  Japan         2001--2014    CR   653          ✓                      7

Abbreviations: C=colon only; CR=colon and rectum; NA=not available; R=rectum only.

###### Methods of defining tumour budding among included studies

  **Author**           **Year**   **Staining method**           **Definition of budding focus**                                             **Tumour budding method**
  ------------------- ---------- --------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------
  Hase                   1993             H&E                     Cluster of \<5 cancer cells                         Graded into two groups: none/mild or moderate/severe at invasive front
  Ueno                   2002             H&E                     Cluster of \<5 cancer cells                                                    \>5 Budding foci
  Okuyama                2002             H&E                     Cluster of \<6 cancer cells                                              ⩾1 Budding focus (Morodomi)
  Okuyama                2003             H&E                     Cluster of \>4 cancer cells                                                    ⩾1 Budding focus
  Ueno                   2004             H&E                     Cluster of \<5 cancer cells                                                    \>9 Budding foci
  Prall                  2005       Cytokeratin/IHC               Cluster of \<5 cancer cells                                                   \>24 Budding foci
  Wang                   2005             H&E                     Cluster of \>4 cancer cells                                              ⩾1 Budding focus (Morodomi)
  Yasuda                 2007             H&E           Cluster of an unspecified number of cancer cells                                     ⩾1 Budding focus (Hase)
  Kanazawa               2008             H&E           Cluster of an unspecified number of cancer cells   Mild: \<1/3 invasive margin Moderate: 1/3--2/3 invasive margin Severe: \>2/3 invasive margin
  Nakamura               2008             H&E           Cluster of an unspecified number of cancer cells                                      As per Kanazawa above
  Yamauchi               2008             H&E                     Cluster of \<5 cancer cells                                            \>4 Budding foci (Ueno modified)
  Lugli                  2009       Cytokeratin/IHC               Cluster of \<6 cancer cells                                                   \>16 Buds per hpf
  Ogawa                  2009       Cytokeratin/IHC               Cluster of \<5 cancer cells                                                    \>9 Budding foci
  Wang                   2009             H&E                     Cluster of \<5 cancer cells                                                    ⩾1 Budding focus
  Homma                  2010             H&E                     Cluster of \<5 cancer cells                        Graded none, mild, mod, severe but did not delineate what comprised each
  Kajiwara               2010             H&E                     Cluster of \<5 cancer cells                                                    \>9 Budding foci
  Komori                 2010             H&E                     Cluster of \<5 cancer cells                                            \>4 Budding foci (Ueno modified)
  Tateishi               2010             H&E                     Cluster of \<5 cancer cells                                                ⩾1 Budding focus (Ueno)
  Akishima-Fukasawa      2011             H&E                     Cluster of \<5 cancer cells                                                \>4 Budding foci (Ueno)
  Reggiani Bonetti       2011             H&E                     Cluster of \<6 cancer cells                                                \>4 Budding foci (Ueno)
  Betge                  2012             H&E                     Cluster of \<5 cancer cells                                            \>9 Budding foci (Ueno modified)
  Nakadoi                2012             H&E                     Cluster of \<6 cancer cells                                            \>4 Budding foci (Ueno modified)
  Sert Bektas            2012             H&E                     Cluster of \<5 cancer cells                                            \>9 Budding foci (Ueno modified)
  Wada                   2013             H&E                     Cluster of \<5 cancer cells                                                \>4 Budding foci (Ueno)
  Zlobec                 2012       Cytokeratin/IHC               Cluster of \<6 cancer cells                                                    \>5 Budding foci
  Nishida                2014             H&E                     Cluster of \<5 cancer cells                                                \>4 Budding foci (Ueno)
  Huh                    2014             H&E                     Cluster of \<5 cancer cells                                                    \>5 Budding foci
  Lai                    2014             H&E                     Cluster of \<5 cancer cells                                            \>9 Budding foci (Ueno modified)
  Ryu                    2014             H&E                     Cluster of \<5 cancer cells                                                \>4 Budding foci (Ueno)
  Gilardoni              2014             NS                      Cluster of \<5 cancer cells                                                \>4 Budding foci (Ueno)
  Macias-Garcia          2014             NS                      Cluster of \<5 cancer cells                                           \>10 Budding foci (Ueno modified)
  Tristante              2014             NS                                   NS                                                                       NS
  Barresi                2016             H&E                     Cluster of \<5 cancer cells                                                \>4 Budding foci (Ueno)
  Miyachi                2015             H&E                     Cluster of \<5 cancer cells                                                \>4 Budding foci (Ueno)

Abbreviations: H&E=haematoxylin and eosin; IHC=Immunohistochemistry; NS, not significant.
